OBJECTIVES: The adjuvant chemotherapy for stage III Colon Cancer is based in oxaliplatin for 6 months. FOLFOX-4, FLOX and XELOX were very similar results in efficacy and safety. There are some differences in total doses and form of the application. We present the differences in direct and indirect costs of the 3 schemes in the National Cancer Institute (NCI) of Mexico. METHODS: We analyzed 130 patients with stage III Colon Cancer treated in the NCI of Mexico, from January 2004 to August 2010. The body surface mean was 1.62 and the costs were calculated based on current prices-government in November 2010. We considered the following costs: 1) Chemotherapy / BS , 2) Prophylactic anti-emetics, 3) Use of central catheter (patients with XELOX, not used catheter), 4) Medical offices, 5) Laboratory tests, 6) Adverse events grade 3-4 (used the frequency of reports of Andre T 2004/FOLFOX, Kuebrer JP 2007/FLOX and Schomll HJ 2007/XELOX) and 7) Number of visits to the Hospital and indirect costs at each visit (cost for visit was $ 39.68 US). All costs was report in US dollars ($ 12.50 Mexican pesos = 1 dollar US) RESULTS: The estimated costs incurred by adjuvant chemotherapy regimen are reported as follows (FLOX, FOLFOX-4, XELOX): Chemotherapy ($13,349, $13,685, $15,365), Anti-emetics ($326, $433, $288), Subclavian catéter-maintenance ($237, $237, $0), QT – application ($764 $1,433, $352), Blood tests ($422, $563, $376), Medical offices ($405, $527, $365), Adverse events grade 3-4  ($726, $568, $371), Hospital visits (number) (40, 61, 17). Indirects costs for visit $1,587, $2,420, $675). The total cost of the treatment is ($17,817, $19,866, $ 17,790). CONCLUSIONS: The FOLFOX scheme was more expensive with the highest number of hospital visits. The scheme XELOX is more practice, less expensive, less visit at the hospital and with less impact on lifestyle.